http://www.alliedminds.com/

"Allied Minds is an innovation company that forms, funds, manages and builds startups based on early-stage technology originating from U.S. universities and federally funded research institutions. We created a new business model for overcoming early-stage development gap between basic research and commercial development. Our investors are aligned with our vision that cutting-edge invention is an attractive, yet under-developed, asset class. We review numerous ideas but only select opportunities with potential to deliver outsized returns. We create subsidiaries led by seasoned management who know how to turn academic breakthroughs into commercial products and then take them to market. We provide our subsidiaries with capital resources, from seed to self-sustainment. Our aim is to promote growth, generate jobs, foster innovation and create societal benefit."

This has gone way below its IPO price in 2014. Now 168p as Invesco has reduced its stake in Allied Minds.

Numis today reaffirms its hold investment rating on Allied Minds PLC (LON:ALM) and set its price target at 165p.

Jefferies International today (03/05/17) reaffirms its hold investment rating on Allied Minds PLC (LON:ALM) and cut its price target to 176p (from 195p).

StockMarketWire.com
Allied Minds portfolio company BridgeSat has completed a $6m series A funding round, including participation from Space Angels, an early stage investment group comprising experts in the Space 2.0 field.

Allied Minds said the fundraise was completed at a pre-money valuation of $15m, up from the previous valuation of $7m.

It said proceeds would be used to accelerate the three core elements of BridgeSat's solution: space terminal (the equipment fixed to customer satellites), ground stations (receiving the data from space) and network (transmitting the data to end customers via cloud based software).

Allied Minds chief executive Jill Smith said: "We are excited by the rapid progress BridgeSat has made in advancing the key elements of its optical downlink network; a technology that has the potential to unlock significant benefits for the large and fast growing LEO data downlink market.

"The participation of Space Angels in this funding round is an important validation for the business, and is consistent with our objective to broaden Allied Minds' funding syndicate and secure investment from strategic and independent financial investors at an earlier stage in our subsidiaries' development.

"The BridgeSat fundraise follows the successful Series A round for HawkEye 360 completed at the end of 2016, and underlines Allied Minds' growing expertise in the satellite and data management verticals."

StockMarketWire.com
Allied Minds portfolio company Signature Medical has completed a $2.5 million series A preferred financing round, including participation by Riot Ventures, an early stage investment fund focused on emerging technology, and Bose Corporation, a global leader in audio innovation.

Signature Medical is developing wearable devices using acoustic signature analysis and artificial intelligence allied to cloud-based technology to evaluate and monitor patients remotely and on a real time basis.

Its lead AcoustiCare device is designed for patients with heart failure and other indications.

Proceeds from the financing will be used to fund product development.

Allied Minds president and chief executive Jill Smith said: "We are pleased to have secured participation by Riot and Bose in the funding for this high potential company, consistent with our desire to attract investment and validation from strategic and financial partners earlier in the investment life cycle where we see benefits from doing so, as we have done recently with our HawkEye 360 and BridgeSat series A rounds."

StockMarketWire.com
Allied Minds invested $22.4 million into its portfolio companies in the six months ended 30 June.

Net cash and investments at 30 June totalled $177.0m (FY16: $226.1m), of which $113.3m was held at parent level.

Other financial highlights:
- Revenue: $2.0 million (HY16: $1.3m)

- Loss for the period: $58.2 million (HY16: $52.2m), of which $44.6 million attributable to Allied Minds (HY16: $41.2m)

- The directors estimate that as of 30 June the group subsidiary ownership adjusted value was $415.8 million ($416.2m as last reported)

On 5 April Allied Minds announced a restructuring, ceasing operations at 7 subsidiaries: Biotectix; Cephalogics; CryoXtract; ProGDerm (dba Novare Pharmaceuticals); Optio Labs; RF Biocidics; and Soundcure / Tinnitus Treatment Solutions.

The group said the the plan had been substantially completed with two of the companies (Biotectix and RF Biocidics) in final stages of the process. 4

President and chief executive Jill Smith said: "We have set out clear goals for the Group with the aim of sharpening capital allocation discipline, including: transitioning to thematic investing; securing earlier and broader syndication of investment partnerships for our portfolio companies where we see scope to validate and accelerate the path to commercialisation; and strengthening the governance and leadership of our portfolio companies.

"Actions undertaken since April across our investment, syndication and operating activities have been consistent with these objectives.

"We have also set out clear goals (MBOs) for our top six companies and ABLS, based on material and commercially relevant milestones, designed to bring about tangible progress towards commercialisation.

"In the short period of time since April, these subsidiaries have progressed well against their respective MBOs, with further achievements expected for the balance of the year.

"I look forward to building on these initial steps with the team as we continue to focus on our objective to drive shareholder value by realising liquidity events that deliver attractive returns for our investors and stakeholders, and accelerating the growth of our underlying business platform."

Numis today upgrades its investment rating on Allied Minds PLC (LON:ALM) to buy (from hold) and raised its price target to 170p (from 165p).

StockMarketWire.com
Allied Minds subsidiary Spin Transfer Technologies and Tokyo Electron have signed an agreement for a collaborative engineering programme for next-generation SRAM and DRAM-class ST-MRAM devices.

Allied Minds said the combination of STT's ST-MRAM technology and TEL's advanced PVD MRAM deposition tool would allow the companies to quickly develop processes for the highest density and endurance devices.

StockMarketWire.com
SciFluor Life Sciences, a subsidiary of Allied Minds, has announced positive top-line results of a phase 1/2 trial studying the treatment of 'wet' age-related macular degeneration patients with SF0166, the company's lead eye drop drug for back of the eye diseases.

The double masked phase 1/2 study assessed the safety, tolerability and preliminary efficacy of SF0166 in 42 evaluable subjects with neovascular (wet) AMD who were randomised 1:1 to self-administer an eye drop containing either a 2.5% or a 5% solution of SF0166 twice-a-day for 28 days.

It said the primary outcome measure of safety was clearly achieved with no drug-related serious adverse events observed in the study throughout the 28-day course of treatment as well as during the 28-day follow-up period.

Ocular adverse events were recorded in the treated eyes of 5 patients; all events were mild or moderate in severity, with one considered possibly drug-related.

Credit Suisse today reaffirms its neutral investment rating on Allied Minds PLC (LON:ALM) and cut its price target to 110p (from 175p).

2 years ago these were 450p a share now 50p.

bargain.